JP2024526939A5 - - Google Patents
Info
- Publication number
- JP2024526939A5 JP2024526939A5 JP2024503840A JP2024503840A JP2024526939A5 JP 2024526939 A5 JP2024526939 A5 JP 2024526939A5 JP 2024503840 A JP2024503840 A JP 2024503840A JP 2024503840 A JP2024503840 A JP 2024503840A JP 2024526939 A5 JP2024526939 A5 JP 2024526939A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- ester
- progression
- rate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163224690P | 2021-07-22 | 2021-07-22 | |
| US202163224674P | 2021-07-22 | 2021-07-22 | |
| US202163224679P | 2021-07-22 | 2021-07-22 | |
| US63/224,679 | 2021-07-22 | ||
| US63/224,674 | 2021-07-22 | ||
| US63/224,690 | 2021-07-22 | ||
| PCT/US2022/038072 WO2023004151A1 (en) | 2021-07-22 | 2022-07-22 | Methods for inhibiting the progression of oxidative retinal diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024526939A JP2024526939A (ja) | 2024-07-19 |
| JP2024526939A5 true JP2024526939A5 (enExample) | 2024-07-29 |
Family
ID=84979648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024503840A Pending JP2024526939A (ja) | 2021-07-22 | 2022-07-22 | 酸化的網膜疾患の進行を抑制する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250099415A1 (enExample) |
| EP (1) | EP4373479A4 (enExample) |
| JP (1) | JP2024526939A (enExample) |
| KR (1) | KR20240036651A (enExample) |
| AU (1) | AU2022313207A1 (enExample) |
| CA (1) | CA3227139A1 (enExample) |
| IL (1) | IL310210A (enExample) |
| WO (1) | WO2023004151A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024049497A1 (en) * | 2022-09-02 | 2024-03-07 | Biojiva Llc | Pharmaceutical compositions of d10-docosahexaenoic acid or esters thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060270739A1 (en) * | 2005-04-28 | 2006-11-30 | Trustees Of Tufts College | Synergistic effects of docosahexaenoic acid (DHA) and carotenoid absorption on macular pigmentation |
| WO2009018333A2 (en) * | 2007-07-30 | 2009-02-05 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Dha and pedf, a therapeutic composition for nerve and retinal pigment epithelial cells |
| US20100324138A1 (en) * | 2007-10-29 | 2010-12-23 | Bazan Nicolas G | Lipoxin A4 Protection for Retinal Cells |
| WO2012148930A2 (en) * | 2011-04-26 | 2012-11-01 | Retrotope, Inc. | Oxidative retinal diseases |
| EP3950649A1 (en) * | 2015-11-23 | 2022-02-09 | Retrotope, Inc. | Site-specific isotopic labeling of 1, 4-diene systems |
| EP3880194A4 (en) * | 2018-11-15 | 2022-11-09 | Retrotope, Inc. | DEUTERED COMPOUNDS, COMPOSITIONS AND USES |
-
2022
- 2022-07-22 EP EP22846695.9A patent/EP4373479A4/en active Pending
- 2022-07-22 JP JP2024503840A patent/JP2024526939A/ja active Pending
- 2022-07-22 CA CA3227139A patent/CA3227139A1/en active Pending
- 2022-07-22 AU AU2022313207A patent/AU2022313207A1/en active Pending
- 2022-07-22 KR KR1020247005941A patent/KR20240036651A/ko active Pending
- 2022-07-22 WO PCT/US2022/038072 patent/WO2023004151A1/en not_active Ceased
- 2022-07-22 US US18/291,016 patent/US20250099415A1/en active Pending
- 2022-07-22 IL IL310210A patent/IL310210A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3558458B1 (en) | Glyceryl 3-hydroxybutyrates for migraine symptom management | |
| JP4151853B2 (ja) | エイコサペンタエン酸および／またはステアリドン酸を含む治療用薬剤 | |
| AU2014236004B2 (en) | Compositions and methods for producing elevated and sustained ketosis | |
| TWI228041B (en) | Highly purified ethyl EPA and EPA derivatives for psychiatric and neurological disorders | |
| JP4596734B2 (ja) | スタチン副作用の処置 | |
| JP2019048843A5 (enExample) | ||
| KR20040004652A (ko) | 조효소 ｑ 및 에이코사펜타에노산（ｅｐａ） | |
| JPH06157303A (ja) | 脂肪酸治療 | |
| CN1638753A (zh) | 脂肪酸治疗效果的强化 | |
| CN1104494A (zh) | 治疗精神分裂症的药物制剂 | |
| JP2025510369A5 (enExample) | ||
| NZ577731A (en) | Compositions and methods for treatment of multiple sclerosis | |
| JP2022521233A5 (enExample) | ||
| JP2024526939A5 (enExample) | ||
| US6288026B1 (en) | Process and composition for treating diseases with an oil-in-water emulsion | |
| US8299121B2 (en) | Softgel of NLKJ for treating prostate diseases | |
| JP2025031720A5 (enExample) | ||
| CA2364606C (en) | Oil-in-water emulsion for the use as medicament or for producing a medicament | |
| McCarty | High-chromium yeast for acne? | |
| JPS5998018A (ja) | 老化治療剤 | |
| JP2024526939A (ja) | 酸化的網膜疾患の進行を抑制する方法 | |
| JP5952556B2 (ja) | 褥瘡治療剤 | |
| RU2657812C2 (ru) | Способ лечения кожных проявлений склеродермии | |
| WO2005046668A1 (ja) | 言語障害予防・治療剤 | |
| JP5710150B2 (ja) | 潜伏性感染疾患の再発抑制剤 |